Abstract：
Intestinal transplantation is a complex technical procedure that provides patients suffering from end-stage intestinal failure an opportunity to enjoy improved quality of life, nutrition and survival. Compared to other types of organ transplants, it is a relatively new advancement in the field of organ transplantation. Nevertheless, great advances have been made over the past few decades to the present era, including the use of ischemic preconditioning, gene therapy, and addition of pharmacological supplements to preservation solutions. However, despite these strides, intestinal transplantation is still a challenging endeavor due to several factors. Notable among them is ischemia-reperfusion injury (IRI), which results in loss of cellular integrity and mucosal barrier function. In addition, IRI causes graft failure, delayed graft function, and decreased graft and recipient survival. This has necessitated the search for novel therapeutic avenues and improved transplantation protocols to prevent or attenuate intestinal IRI. Among the many candidate agents that are being investigated to combat IRI and its associated complications, nitric oxide (NO). NO is an endogenously produced gaseous signaling molecule with several therapeutic properties. The purpose of this mini-review is to discuss IRI and its related complications in intestinal transplantation, and NO as an emerging pharmacological tool against this challenging pathological condition. i.
摘要：
肠移植是一项复杂的技术程序，为患有终末期肠衰竭的患者提供了享受改善生活质量的机会，营养和生存。与其他类型的器官移植相比，这是器官移植领域相对较新的进步。然而，在过去的几十年里取得了巨大的进步，包括使用缺血预处理，基因治疗,并在保存溶液中添加药物补充剂。然而,尽管取得了这些进展,由于几个因素，肠道移植仍然是一项具有挑战性的工作。其中值得注意的是缺血再灌注损伤（IRI），这导致细胞完整性和粘膜屏障功能的丧失。此外,IRI导致移植失败,延迟的移植物功能，移植物和受体存活率下降。这需要寻找新的治疗途径和改进的移植方案以预防或减弱肠IRI。在许多正在研究的对抗IRI及其相关并发症的候选药物中，一氧化氮（NO）。NO是一种内源性产生的气态信号分子，具有几种治疗特性。这篇小型综述的目的是讨论肠移植中的IRI及其相关并发症，和NO作为一种新兴的药理学工具来对抗这种具有挑战性的病理状况。I.
